モリシジン·塩酸塩

プロパティ

安全情報

説明

Moricizine hydrochloride is a phenothiazine derivative with antiarrhythmic activity developed by the Soviet Academy of Medical Sciences. It is licensed to Dupont-Sanko in a joint venture. Moricizine hydrochloride is the first drug licensed to a U.S. company by the Soviet Union and was introduced by Dupont in the U.S. in 1990 for specific use in Iife-threatening ventricular arrhythmias. This narrow indication reflects its proarrhythmic potential. The incidence of this adverse reaction, however, is lower than that of other antiarrhythmic agents.